Yet, they assessed the validity of GCP III as an off-target in the salivary gland before.56 The authors concluded that the uptake of PSMA ligands is still mediated through the existing PSMA in the salivary glands albeit through a different process than that in prostate cancer. The gene discussed is FOLH1; the disease is prostate carcinoma.